FC Stock News
Tuesday, February 20, 2007
Failed Trial For BioMarin
BioMarin Pharmaceutical Inc. (BMRN) issued guidance for higher sales and a smaller loss, but its hypertension drug failed a mid-stage clinical trial sending the stock price plunging $2.45 to close at $18.00.
posted by FC Market News at
2:31 PM
0 Comments:
Post a Comment
<< Home
About Me
Name:
FC Market News
View my complete profile
Previous Posts
Sirius And XM Satellite To Merge
Empire Resorts Receives Approval
Vulcan Bids On Florida Rock
Scotts Miracle-Gro Declares Dividend
Revenue Falls Short For Captaris
Campbell Reports Higher Earnings
Earnings Rise For Mohawk Industries
Onyx Narrows Losses
Earnings Tumbled For Career Education
Fieldstone Investment To Be Acquired
0 Comments:
Post a Comment
<< Home